Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
October 15 2024 - 5:25AM
UK Regulatory
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third
Quarter of 2024
Company Announcement
- Net sales of
DARZALEX® in the third
quarter of 2024 totaled USD 3,016 million
- Genmab receives royalties on worldwide net sales from
Janssen Biotech, Inc. (Janssen)
COPENHAGEN, Denmark; October 15, 2024 –
Genmab A/S (Nasdaq: GMAB) announced today
that worldwide net trade sales of
DARZALEX®
(daratumumab), including sales of the
subcutaneous (SC) product (daratumumab and
hyaluronidase-fihj, sold under the tradename
DARZALEX
FASPRO®
in the U.S.),
as reported by Johnson & Johnson were USD 3,016 million
in the third quarter of 2024. Net trade sales were USD
1,684 million in the U.S. and USD 1,332 million in the rest of the
world. Genmab receives royalties on the worldwide net sales of
DARZALEX, both the intravenous and SC products, under the exclusive
worldwide license to Janssen to develop, manufacture and
commercialize daratumumab.
About Genmab
Genmab is an international biotechnology company with a core
purpose of guiding its unstoppable team to strive toward improving
the lives of patients with innovative and differentiated antibody
therapeutics. For 25 years, its passionate, innovative and
collaborative team has invented next-generation antibody technology
platforms and leveraged translational, quantitative and data
sciences, resulting in a proprietary pipeline including bispecific
T-cell engagers, antibody-drug conjugates, next-generation immune
checkpoint modulators and effector function-enhanced antibodies. By
2030, Genmab’s vision is to transform the lives of people with
cancer and other serious diseases with knock-your-socks-off
(KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors
included in Genmab’s most recent Annual Report on Form 20-F and
other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at
www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following
trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination
with the Y-shaped Genmab logo®;
HuMax®;
DuoBody®;
HexaBody®;
DuoHexaBody®,
HexElect® and
KYSO®.
DARZALEX® and DARZALEX
FASPRO® are trademarks of Johnson
& Johnson.
Company Announcement no. 59
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
- 151024_CA59_DARZALEX Q3 2024 sales
Genmab AS (TG:GE9)
Historical Stock Chart
From Oct 2024 to Nov 2024
Genmab AS (TG:GE9)
Historical Stock Chart
From Nov 2023 to Nov 2024
